A research study to find an indicator of Parkinson’s Disease in blood, urine or spinal fluid using Healthy Volunteers and Parkinson’s Disease patients.
Recruiting
- Conditions
- Parkinson’s Disease
- Registration Number
- NL-OMON20075
- Lead Sponsor
- Denali Therapeutics
- Brief Summary
A
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- Not specified
- Target Recruitment
- 35
Inclusion Criteria
Groups A and B
1. Confirmed clinical diagnosis of Parkinson’s disease by a qualified neurologist,
Exclusion Criteria
8.Exclusion Criteria
Study & Design
- Study Type
- Observational non invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method - LRRK2 phosphorylation (pS935, total LRRK2 and pS935/Total LRRK2 ratio) in<br> PBMCs, Whole blood, Neutrophils, Urine exosomes, CSF exosomes.<br><br /><br /><br>- Rab GTPase phosphorylation in PBMCs, whole blood, Neutrophils, Urine exosomes, CSF exosomes, lipidomic, metabolomic and/or proteomic analysis of CSF Urine and/or Plasma. <br /><br /><br><br>- CSF lysosomal enzyme activity, Cathepsin D, Glucocerebrosidase.<br><br /><br /><br>- CSF alpha-synuclein, Total, pS129 and/or Oligomeric alpha-synuclein. <br><br /><br /><br>- CSF and plasma cytokines (65-cytokine panel)<br><br /><br /><br>- Cellular analyses of fibroblast cultures, e.g. lysosome imaging, immunohistochemistry for lysosome markers (LAMP1, LAMP2, etc), lysotracker, LRRI€pS93S and pRabl0 immunoassays, LC/MS analysis, protein turnover analysis, and Lysosome enzyme activity assays.<br /><br /><br><br>- Potential other parameters related to LRRK2 that become available<br>
- Secondary Outcome Measures
Name Time Method